NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

10630	Companies
225961	Keywords
154508	Articles
119607	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 05/15/2026 at 14:35, 1 month 9 days ago

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces a registered direct offering of common shares and warrants to a fundamental institutional investor for gross proceeds of approximately US$2 million. D. Boral Capital LLC acts as the exclusive placement agent for the Offering

NanoViricides Securities Purchase Agreement Registered Direct Offering D. Boral Capital LLC Fundamental Institutional Investor
BRIEF

published on 05/15/2026 at 14:05, 1 month 9 days ago

NanoViricides fait état de progrès dans le développement du NV-387 dans son dernier document déposé auprès de la SEC.

NanoViricides NV-387 Essai De Phase II Médicament Orphelin Traitement De La Variole Du Singe
BRIEF

published on 05/15/2026 at 14:05, 1 month 9 days ago

NanoViricides Reports Progress on NV-387 in Latest SEC Filing

NanoViricides NV-387 Phase II Trial Orphan Drug Monkeypox Treatment
PRESS RELEASE

published on 05/15/2026 at 14:00, 1 month 9 days ago

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II
NanoViricides, Inc. files Quarterly Report on Form 10-Q with the SEC. NV-387 advances in Phase II trial for Measles, MPox, and Smallpox treatments. Financial updates disclosed

NV-387 Form 10-Q NanoViricides Inc. Phase II Trial Financial Update
BRIEF

published on 05/11/2026 at 14:35, 1 month 13 days ago

NanoViricides Highlights Need for Broad-Spectrum Antivirals Post-Hantavirus Incident

NanoViricides NV-387 Broad-spectrum Antiviral Hantavirus MV Hondius
BRIEF

published on 05/11/2026 at 14:35, 1 month 13 days ago

NanoViricides souligne le besoin d'antiviraux à large spectre après l'incident du hantavirus

NanoViricides NV-387 Antiviral À Large Spectre Hantavirus MV Hondius
PRESS RELEASE

published on 05/11/2026 at 14:30, 1 month 13 days ago

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
NanoViricides, Inc. highlights the need for a revolutionary antiviral drug like NV-387 as response to Andes hantavirus incident on a cruise ship, emphasizing potential global epidemic risk

NV-387 NanoViricides Inc. Antiviral Drug Andes Hantavirus Global Epidemic
BRIEF

published on 05/04/2026 at 14:35, 1 month 20 days ago

NanoViricides' NV-387 Receives Orphan Drug Designation for Measles Treatment

NanoViricides NV-387 Orphan Drug Designation Measles Treatment US FDA
BRIEF

published on 05/04/2026 at 14:35, 1 month 20 days ago

Le NV-387 de NanoViricides obtient la désignation de médicament orphelin pour le traitement de la rougeole

NanoViricides NV-387 Désignation De Médicament Orphelin FDA Américaine Traitement De La Rougeole
PRESS RELEASE

published on 05/04/2026 at 14:30, 1 month 20 days ago

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
NanoViricides, Inc. receives US FDA Orphan Drug Designation for antiviral drug NV-387, targeting Measles treatment. The drug shows strong efficacy in in vivo studies

NanoViricides NV-387 Orphan Drug Designation Antiviral Drug Measles Treatment

Accesswire

Published on 06/25/2026 at 00:30, 5 hours 40 minutes ago

Northern Dynasty Reports Annual General Meeting Results and Welcomes New Directors
Published on 06/24/2026 at 23:05, 7 hours 5 minutes ago

Polaris Modifies Quorum Requirement for Upcoming AGM
Published on 06/24/2026 at 22:15, 7 hours 55 minutes ago

Organto Foods Announces Annual General Meeting Results
Published on 06/24/2026 at 21:20, 8 hours 50 minutes ago

Taranis to Explore New Properties East of Thor Mineral Resource
Published on 06/24/2026 at 20:10, 10 hours ago

Fox River Obtains Final Order Approving Plan of Arrangement With Avenir Minerals Limited

View all ACCESSWIRE

EQS Group

Published on 06/25/2026 at 03:20, 2 hours 49 minutes ago

ZTT at Intersolar Europe 2026: Full-Industry-Chain Strength Powering a Low-Carbon Future
Published on 06/24/2026 at 23:57, 6 hours 13 minutes ago

OHB: Upsized private placement worth EUR 900 million successfully completed
Published on 06/24/2026 at 20:54, 9 hours 15 minutes ago

EQS-Adhoc: Branicks Group AG sets out timetable for the publication of its 2025 annual and consolidated financial statements
Published on 06/24/2026 at 18:29, 11 hours 41 minutes ago

Designated Person Notification
Published on 06/24/2026 at 18:29, 11 hours 41 minutes ago

Designated Person Notification

Les Echos

Published on 06/24/2026 at 19:00, 11 hours 10 minutes ago

ALTAREA - Succès de l’option pour le paiement du dividende en actions : taux de souscription de 78,5 %
Published on 06/24/2026 at 18:00, 12 hours 10 minutes ago

Annual Results 2025-26
Published on 06/24/2026 at 18:00, 12 hours 10 minutes ago

CP résultats annuels 2025-26
Published on 06/24/2026 at 18:00, 12 hours 10 minutes ago

KERLINK : Assemblée générale mixte des actionnaires du 23 juin 2026 Seconde convocation le 9 juillet 2026.
Published on 06/24/2026 at 17:45, 12 hours 25 minutes ago

Air Liquide poursuit son développement au Kazakhstan avec un investissement clé pour le complexe industriel de Silleno

View all LES ECHOS COMFI WIRE